In a recent report, MTE was able to suppress tumor angiogenesis in vivo and in vitro through decreasing VEGF-A and VEGFR-2 expression in human umbilical vein endothelial cells (HUVECs) and VEGF-A expression in HepG2 (13). This evidence concerns the gene VEGFA and neoplasm.